WAFP, WCAAP, Other Stakeholders Sign Letter on RSV Vaccines

WAFP President Carla Ainsworth, MD, MPH, and representatives from other medical and public health societies signed a letter to raise awareness of administering RSV vaccines for Washington’s youngest patients.

Nirsevimab (trade name Beyfortus) can be administered for all infants under 8 months old who are born during or entering their first RSV season. It can also be administered for children aged 8-19 months who at increased risk of severe RSV illness and entering their second RSV season.

RSVpreF (trade name Abrysvo) can be administered to pregnant patients starting at the 32nd week of gestation and before the 37th week of gestation. Both can be safely administered with other vaccinations.

When physicians strongly recommend preventive treatment, patients listen. We hope you will join WAFP and our partners in recommending these vaccines to help keep Washington’s babies safe for this and future RSV seasons.

Other signatories on the letter include the Washington Chapter of the American Academy of Pediatrics; the Washington Section of the American College of Obstetrics and Gynecology; The Rural Collaborative; the Washington State Association of Local Public Health Officials; the Washington State Obstetrical Association; the Washington State Perinatal Quality Collaborative; and the ACOG liaison to the Advisory Committee on Immunization Practice.